Loretta Lazzarato

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1005564/publications.pdf

Version: 2024-02-01

74	2,349	218677	223800
papers	citations	26 h-index	46 g-index

77	77	77	3522
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. Journal of Experimental Medicine, 2011, 208, 1949-1962.	8.5	547
2	Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors. Drug Resistance Updates, 2020, 50, 100682.	14.4	160
3	Antiinflammatory, Gastrosparing, and Antiplatelet Properties of New NO-Donor Esters of Aspirin. Journal of Medicinal Chemistry, 2003, 46, 747-754.	6.4	92
4	A New Class of Ibuprofen Derivatives with Reduced Gastrotoxicity. Journal of Medicinal Chemistry, 2001, 44, 3463-3468.	6.4	72
5	Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. European Journal of Medicinal Chemistry, 2016, 123, 523-531.	5.5	64
6	Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity. ACS Medicinal Chemistry Letters, 2011, 2, 494-497.	2.8	63
7	Mitochondrial-Targeting Nitrooxy-doxorubicin: A New Approach To Overcome Drug Resistance. Molecular Pharmaceutics, 2013, 10, 161-174.	4.6	62
8	NO-Donor COX-2 Inhibitors. New Nitrooxy-Substituted 1,5-Diarylimidazoles Endowed with COX-2 Inhibitory and Vasodilator Properties. Journal of Medicinal Chemistry, 2007, 50, 1449-1457.	6.4	58
9	NO-Donor Phenols:â€‰ A New Class of Products Endowed with Antioxidant and Vasodilator Properties. Journal of Medicinal Chemistry, 2006, 49, 2886-2897.	6.4	46
10	H₂S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance. Journal of Medicinal Chemistry, 2016, 59, 4881-4889.	6.4	43
11	Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. Journal of Medicinal Chemistry, 2017, 60, 8647-8660.	6.4	43
12	Synthesis and Biological Evaluation of the First Example of NO-Donor Histone Deacetylase Inhibitor. ACS Medicinal Chemistry Letters, 2013, 4, 994-999.	2.8	42
13	Synthesis and antimalarial activities of some furoxan sulfones and related furazans. European Journal of Medicinal Chemistry, 2005, 40, 1335-1340.	5.5	41
14	Methotrexate-Loaded Solid Lipid Nanoparticles: Protein Functionalization to Improve Brain Biodistribution. Pharmaceutics, 2019, 11, 65.	4.5	39
15	Mechanistic Insights into Cyclooxygenase Irreversible Inactivation by Aspirin. ChemMedChem, 2009, 4, 939-945.	3.2	35
16	Searching for New NO-Donor Aspirin-like Molecules: A New Class of Nitrooxy-acyl Derivatives of Salicylic Acid. Journal of Medicinal Chemistry, 2008, 51, 1894-1903.	6.4	34
17	The Furoxan System: Design of Selective Nitric Oxide (NO) Donor Inhibitors of COX-2 Endowed with Anti-Aggregatory and Vasodilating Activities. Chemistry and Biodiversity, 2005, 2, 886-900.	2.1	32
18	(Nitrooxyacyloxy)methyl Esters of Aspirin as Novel Nitric Oxide Releasing Aspirins. Journal of Medicinal Chemistry, 2009, 52, 5058-5068.	6.4	32

#	Article	IF	Citations
19	Furazan and furoxan sulfonamides are strong Î±-carbonic anhydrase inhibitors and potential antiglaucoma agents. Bioorganic and Medicinal Chemistry, 2014, 22, 3913-3921.	3.0	32
20	A Nonmetalâ€Containing Nitric Oxide Donor Activated with Singleâ€Photon Green Light. Chemistry - A European Journal, 2017, 23, 9026-9029.	3.3	32
21	New Nitric Oxide or Hydrogen Sulfide Releasing Aspirins. Journal of Medicinal Chemistry, 2011, 54, 5478-5484.	6.4	31
22	Lightâ€Tunable Generation of Singlet Oxygen and Nitric Oxide with a Bichromophoric Molecular Hybrid: a Bimodal Approach to Killing Cancer Cells. ChemMedChem, 2016, 11, 1371-1379.	3.2	30
23	A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages. Journal of Inflammation, 2008, 5, 12.	3.4	28
24	Designing Multitarget Antiâ€inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonistsâ€“COXâ€2 Inhibitors. ChemMedChem, 2012, 7, 1647-1660.	3.2	28
25	Searching for new NO-donor aspirin-like molecules: Furoxanylacyl derivatives of salicylic acid and related furazans. Bioorganic and Medicinal Chemistry, 2011, 19, 5852-5860.	3.0	27
26	Doxorubicin-antioxidant co-drugs. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5307-5310.	2.2	27
27	Michael addition of Grignard reagents to tetraethyl ethenylidenebisphosphonate. Journal of Organometallic Chemistry, 2002, 650, 77-83.	1.8	26
28	Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae. Chemistry - A European Journal, 2019, 25, 11080-11084.	3.3	26
29	Design, Biological Evaluation, and Molecular Modeling of Tetrahydroisoquinoline Derivatives: Discovery of A Potent P-Glycoprotein Ligand Overcoming Multidrug Resistance in Cancer Stem Cells. Journal of Medicinal Chemistry, 2019, 62, 974-986.	6.4	26
30	Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5971-5974.	2.2	25
31	Synthesis of NO-Donor Bisphosphonates and Their in-Vitro Action on Bone Resorption. Journal of Medicinal Chemistry, 2005, 48, 1322-1329.	6.4	22
32	Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs). Bioorganic and Medicinal Chemistry, 2010, 18, 2428-2438.	3.0	22
33	A Nitric Oxide-Donor Furoxan Moiety Improves the Efficacy of Edaravone against Early Renal Dysfunction and Injury Evoked by Ischemia/Reperfusion. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-12.	4.0	22
34	Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells. Frontiers in Pharmacology, 2018, 9, 580.	3.5	22
35	A molecular hybrid producing simultaneously singlet oxygen and nitric oxide by single photon excitation with green light. Bioorganic Chemistry, 2019, 85, 18-22.	4.1	22
36	Synthesis and preliminary biological profile of new NO-donor tolbutamide analogues. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3810-3815.	2.2	21

#	Article	IF	Citations
37	Waterâ€Soluble Nitricâ€Oxideâ€Releasing Acetylsalicylic Acid (ASA) Prodrugs. ChemMedChem, 2013, 8, 1199-1209.	3.2	20
38	Structureâ€“Activity Relationship Studies on Tetrahydroisoquinoline Derivatives: [4â€²-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-ylmethyl)biphenyl-4-ol] (MC70) Conjugated through Flexible Alkyl Chains with Furazan Moieties Gives Rise to Potent and Selective Ligands of P-glycoprotein. Journal of Medicinal Chemistry, 2016, 59, 6729-6738.	6.4	20
39	Furoxan Nitric Oxide Donors Disperse Pseudomonas aeruginosa Biofilms, Accelerate Growth, and Repress Pyoverdine Production. ACS Chemical Biology, 2017, 12, 2097-2106.	3.4	20
40	Multitarget drugs: Focus on the NO-donor hybrid drugs. Pure and Applied Chemistry, 2008, 80, 1693-1701.	1.9	19
41	Enhancing doxorubicin anticancer activity with a novel polymeric platform photoreleasing nitric oxide. Biomaterials Science, 2020, 8, 1329-1344.	5.4	19
42	Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth. Chemico-Biological Interactions, 2009, 182, 183-190.	4.0	18
43	Structural and biological characterization of new hybrid drugs joining an HDAC inhibitor to different NO-donors. European Journal of Medicinal Chemistry, 2018, 144, 612-625.	5.5	18
44	Novel antioxidant agents deriving from molecular combination of Vitamin C and NO-donor moieties. Bioorganic and Medicinal Chemistry, 2008, 16, 5199-5206.	3.0	16
45	A generator of peroxynitrite activatable with red light. Chemical Science, 2021, 12, 4740-4746.	7.4	15
46	Nitrooxymethylâ€Substituted Analogues of Celecoxib: Synthesis and Pharmacological Characterization. Chemistry and Biodiversity, 2009, 6, 369-379.	2.1	14
47	NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization. Journal of Pineal Research, 2007, 42, 371-385.	7.4	13
48	A Potent and Selective Pâ€gp Modulator for Altering Multidrug Resistance Due to Pump Overexpression. ChemMedChem, 2016, 11, 374-376.	3.2	13
49	Galactosylated Proâ€“Drug of Ursodeoxycholic Acid: Design, Synthesis, Characterization, and Pharmacological Effects in a Rat Model of Estrogen-Induced Cholestasis. Molecular Pharmaceutics, 2018, 15, 21-30.	4.6	12
50	Aceclofenacâ€“Galactose Conjugate: Design, Synthesis, Characterization, and Pharmacological and Toxicological Evaluations. Molecular Pharmaceutics, 2018, 15, 3101-3110.	4.6	12
51	Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs. Bioorganic and Medicinal Chemistry, 2012, 20, 841-850.	3.0	11
52	A Molecular Hybrid for Mitochondriaâ€Targeted NO Photodelivery. ChemMedChem, 2018, 13, 87-96.	3.2	11
53	Combination of PDT and NOPDT with a Tailored BODIPY Derivative. Antioxidants, 2019, 8, 531.	5.1	10
54	Paracetamolâ€“Galactose Conjugate: A Novel Prodrug for an Old Analgesic Drug. Molecular Pharmaceutics, 2019, 16, 4181-4189.	4.6	10

#	Article	IF	Citations
55	New furoxan derivatives for the treatment of ocular hypertension. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 479-483.	2.2	9
56	Tuning the Hydrophobicity of a Mitochondriaâ€Targeted NO Photodonor. ChemMedChem, 2018, 13, 1238-1245.	3.2	9
57	Synthesis of Some Novel Organic Nitrates and Comparative in Vitro Study of Their Vasodilator Profile. Journal of Medicinal Chemistry, 2009, 52, 4020-4025.	6.4	8
58	Tuning NO release of organelle-targeted furoxan derivatives and their cytotoxicity against lung cancer cells. Bioorganic Chemistry, 2021, 111, 104911.	4.1	8
59	Nitrooxyacyl Derivatives of Salicylic Acid: Aspirinâ€Like Molecules that Covalently Inactivate Cyclooxygenaseâ€1. ChemMedChem, 2011, 6, 523-530.	3.2	7
60	Anti-Pseudomonas activity of 3-nitro-4-phenylfuroxan. Microbiology (United Kingdom), 2018, 164, 1557-1566.	1.8	7
61	Synthesis, chiral HPLC resolution and configuration assignment of 1-phenylglyceryl trinitrate stereomers. Chirality, 2006, 18, 430-436.	2.6	6
62	Structure-Antioxidant Activity Relationships in a Series of NO-Donor Phenols. ChemMedChem, 2008, 3, 1443-1448.	3.2	6
63	A Rapid Screening for Cytochrome P450 Catalysis on New Chemical Entities: Cytochrome P450 BM3 and 1,2,5-Oxadiazole Derivatives. Journal of Biomolecular Screening, 2013, 18, 211-218.	2.6	6
64	Can We Exploit Î²-Lactamases Intrinsic Dynamics for Designing More Effective Inhibitors?. Antibiotics, 2020, 9, 833.	3.7	6
65	Cryo-EM structures of staphylococcal IsdB bound to human hemoglobin reveal the process of heme extraction. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2116708119.	7.1	6
66	NO release regulated by doxorubicin as the green light-harvesting antenna. Chemical Communications, 2020, 56, 6332-6335.	4.1	5
67	NO in Viral Infections: Role and Development of Antiviral Therapies. Molecules, 2022, 27, 2337.	3.8	5
68	gem-Dinitroalkyl Benzenes: A Novel Class of IOP-Lowering Agents for the Treatment of Ocular Hypertension. ACS Medicinal Chemistry Letters, 2017, 8, 1054-1059.	2.8	4
69	Multitarget Antioxidant NO-Donor Organic Nitrates: A Novel Approach to Overcome Nitrates Tolerance, an Ex Vivo Study. Antioxidants, 2022, 11, 166.	5.1	4
70	Galactosylated Prodrugs: A Strategy to Improve the Profile of Nonsteroidal Anti-Inflammatory Drugs. Pharmaceuticals, 2022, 15, 552.	3.8	3
71	Amphiphilic NO-Donor Antioxidants. ChemMedChem, 2007, 2, 234-240.	3.2	2
72	DNAâ€Targeted NO Release Photoregulated by Green Light. Chemistry - A European Journal, 2020, 26, 13627-13633.	3.3	2

#	Article	IF	Citations
73	Physicochemical profile and in vitro permeation behavior of a new class of non-steroidal anti-inflammatory drug candidates. European Journal of Pharmaceutical Sciences, 2010, 40, 217-221.	4.0	1
74	Development of a New Class of Potential Antiatherosclerosis Agents: NO-Donor Antioxidants.. ChemInform, 2005, 36, no.	0.0	0